Novo Nordisk A/S (NYSE:NVO) Shares Bought by Woodmont Investment Counsel LLC

Woodmont Investment Counsel LLC boosted its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 276.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 110,551 shares of the company's stock after buying an additional 81,163 shares during the quarter. Woodmont Investment Counsel LLC's holdings in Novo Nordisk A/S were worth $9,510,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Folketrygdfondet lifted its holdings in shares of Novo Nordisk A/S by 0.5% in the 4th quarter. Folketrygdfondet now owns 8,903,938 shares of the company's stock worth $765,917,000 after acquiring an additional 40,313 shares during the last quarter. Sustainable Growth Advisers LP raised its position in Novo Nordisk A/S by 23.6% in the 4th quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company's stock worth $459,416,000 after purchasing an additional 1,021,498 shares during the period. Raymond James Financial Inc. purchased a new stake in Novo Nordisk A/S in the 4th quarter worth about $404,910,000. WCM Investment Management LLC boosted its position in shares of Novo Nordisk A/S by 1.0% during the fourth quarter. WCM Investment Management LLC now owns 4,031,124 shares of the company's stock valued at $345,588,000 after buying an additional 40,475 shares during the period. Finally, Amundi grew its stake in shares of Novo Nordisk A/S by 26.4% during the fourth quarter. Amundi now owns 3,311,456 shares of the company's stock valued at $283,615,000 after buying an additional 692,567 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Novo Nordisk A/S Stock Down 2.3 %

NYSE NVO traded down $1.76 during midday trading on Tuesday, hitting $73.57. 8,872,312 shares of the company traded hands, compared to its average volume of 5,438,701. Novo Nordisk A/S has a 52 week low of $73.80 and a 52 week high of $148.15. The company's 50-day simple moving average is $83.01 and its 200-day simple moving average is $99.94. The company has a market cap of $330.15 billion, a PE ratio of 22.36, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S's dividend payout ratio is presently 47.72%.

Analyst Ratings Changes

NVO has been the subject of a number of recent analyst reports. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. StockNews.com lowered Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a report on Friday. BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a report on Monday, December 23rd. Finally, Stifel Nicolaus downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.